Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid Tumors

NCT06049212 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT06049212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06049212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid Tumors
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 26, 2023
Completion date
January 29, 2028
Enrollment
30 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, programmed cell death 1 ligand 1(pdl1, pd-l1), programmed cell death 1 ligand 2 (pdl2, pd-l2), programmed cell death-1 (pd1, pd-1), solid tumors